Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VSV-IFNβ-NIS + avelumab
- Development stage
- Unknown
- Lead developer
- Vyriad
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
VSV-IFNβ-NIS + avelumab is an investigational combination therapy for cancer, particularly solid tumors. VSV-IFNβ-NIS (also known as Voyager-V1 or VV1) is an oncolytic virus therapy derived from vesicular stomatitis virus (VSV), engineered to selectively infect and kill cancer cells. It encodes human interferon beta (IFNβ) to enhance antitumor immune responses and the sodium iodide symporter (NIS) for imaging viral spread. Avelumab is a human monoclonal antibody targeting programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 receptors on T cells, thereby releasing suppression of the immune response against tumor cells. The combination aims to inflame tumors via direct oncolysis and immune activation by the virus, while avelumab further enhances antitumor immunity by inhibiting PD-L1-mediated immunosuppression[4][5][6][8].
- Other names
- VV1VV-1VV 1Voyager V1
02
Targets
LDLR (Low-density lipoprotein receptor)CD274 (Programmed cell death protein 1 ligand 1)NIS (Human sodium iodide symporter)IFNAR (Immune system modulation via type I interferon receptor)IFN-β (Interferon beta)
Beyond the preview
Go deeper on VSV-IFNβ-NIS + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VSV-IFNβ-NIS + avelumab.